The unfolded protein response is activated in the olfactory system in Alzheimer's disease.
Aged
Aged, 80 and over
Alzheimer Disease
/ metabolism
Amyloid beta-Peptides
/ metabolism
Eukaryotic Initiation Factor-2
/ analysis
Female
Humans
Male
Middle Aged
Neurofibrillary Tangles
/ pathology
Neurons
/ metabolism
Olfactory Pathways
/ metabolism
Unfolded Protein Response
/ physiology
eIF-2 Kinase
/ analysis
tau Proteins
/ metabolism
Alzheimer’s disease
Anterior olfactory nucleus
Olfactory bulb
PERK
Unfolded protein response
eIF2α
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
14 07 2020
14 07 2020
Historique:
received:
08
05
2020
accepted:
03
07
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
1
6
2021
Statut:
epublish
Résumé
Olfactory dysfunction is an early and prevalent symptom of Alzheimer's disease (AD) and the olfactory bulb is a nexus of beta-amyloid plaque and tau neurofibrillary tangle (NFT) pathology during early AD progression. To mitigate the accumulation of misfolded proteins, an endoplasmic reticulum stress response called the unfolded protein response (UPR) occurs in the AD hippocampus. However, chronic UPR activation can lead to apoptosis and the upregulation of beta-amyloid and tau production. Therefore, UPR activation in the olfactory system could be one of the first changes in AD. In this study, we investigated whether two proteins that signal UPR activation are expressed in the olfactory system of AD cases with low or high amounts of aggregate pathology. We used immunohistochemistry to label two markers of UPR activation (p-PERK and p-eIF2α) concomitantly with neuronal markers (NeuN and PGP9.5) and pathology markers (beta-amyloid and tau) in the olfactory bulb, piriform cortex, entorhinal cortex and the CA1 region of the hippocampus in AD and normal cases. We show that UPR activation, as indicated by p-PERK and p-eIF2α expression, is significantly increased throughout the olfactory system in AD cases with low (Braak stage III-IV) and high-level (Braak stage V-VI) pathology. We further show that UPR activation occurs in the mitral cells and in the anterior olfactory nucleus of the olfactory bulb where tau and amyloid pathology is abundant. However, UPR activation is not present in neurons when they contain NFTs and only rarely occurs in neurons containing diffuse tau aggregates. We conclude that UPR activation is prevalent in all regions of the olfactory system and support previous findings suggesting that UPR activation likely precedes NFT formation. Our data indicate that chronic UPR activation in the olfactory system might contribute to the olfactory dysfunction that occurs early in the pathogenesis of AD.
Identifiants
pubmed: 32665027
doi: 10.1186/s40478-020-00986-7
pii: 10.1186/s40478-020-00986-7
pmc: PMC7362534
doi:
Substances chimiques
Amyloid beta-Peptides
0
Eukaryotic Initiation Factor-2
0
MAPT protein, human
0
tau Proteins
0
EIF2AK3 protein, human
EC 2.7.11.1
eIF-2 Kinase
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109Références
Neuroscience. 2018 Feb 21;372:289-303
pubmed: 29429526
J Neurosci Res. 2008 Jul;86(9):2091-9
pubmed: 18335524
Neuron. 2008 Dec 26;60(6):988-1009
pubmed: 19109907
Brain. 2017 Oct 1;140(10):2722-2736
pubmed: 28969383
PLoS One. 2010 May 05;5(5):e10489
pubmed: 20463975
Acta Neuropathol. 2015 Sep;130(3):315-31
pubmed: 26210990
Antioxid Redox Signal. 2007 Dec;9(12):2245-54
pubmed: 17979527
Neurodegener Dis. 2012;10(1-4):212-5
pubmed: 22302012
Acta Neuropathol. 2005 Aug;110(2):165-72
pubmed: 15973543
Aging Cell. 2018 Oct;17(5):e12801
pubmed: 29992725
Alzheimer Dis Assoc Disord. 1994 Spring;8(1):38-48
pubmed: 8185881
J Neuropathol Exp Neurol. 2015 Jun;74(6):547-56
pubmed: 25933387
J Alzheimers Dis. 2005 Apr;7(2):149-57; discussion 173-80
pubmed: 15851853
J Neurol. 2002 Oct;249 Suppl 3:III/1-5
pubmed: 12528692
Nat Rev Neurosci. 2014 Apr;15(4):233-49
pubmed: 24619348
Biochem Biophys Res Commun. 2007 Mar 16;354(3):707-11
pubmed: 17254549
Semin Immunopathol. 2013 May;35(3):277-92
pubmed: 23609500
Anat Rec. 1987 May;218(1):73-87
pubmed: 3605663
Ann N Y Acad Sci. 1998 Nov 30;855:708-15
pubmed: 9929675
Am J Pathol. 2009 Apr;174(4):1241-51
pubmed: 19264902
Neuropathol Appl Neurobiol. 2003 Oct;29(5):503-10
pubmed: 14507342
Sci Transl Med. 2013 Oct 9;5(206):206fs37
pubmed: 24107775
Nature. 2012 May 06;485(7399):507-11
pubmed: 22622579
Sci Rep. 2020 Apr 21;10(1):6682
pubmed: 32317654
J Pathol. 2012 Apr;226(5):693-702
pubmed: 22102449
Nat Cell Biol. 2011 Mar;13(3):184-90
pubmed: 21364565
Neurobiol Aging. 1995 May-Jun;16(3):271-8; discussion 278-84
pubmed: 7566337
J Cell Mol Med. 2018 Jul;22(7):3489-3502
pubmed: 29675957
J Comp Neurol. 2016 Nov 1;524(16):3127-481
pubmed: 27418273
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
J Neurol Neurosurg Psychiatry. 1984 Jan;47(1):56-60
pubmed: 6693914
Brain. 2007 Dec;130(Pt 12):3111-23
pubmed: 17716997
Nat Protoc. 2006;1(6):2719-32
pubmed: 17406528
Neuron. 2011 Jul 14;71(1):35-48
pubmed: 21745636
Acta Neuropathol. 2019 Dec;138(6):943-970
pubmed: 31456031
Acta Neuropathol Commun. 2019 Jan 3;7(1):2
pubmed: 30606258
J Neurosci. 2013 May 29;33(22):9498-507
pubmed: 23719816
Neuroreport. 2001 Feb 12;12(2):285-8
pubmed: 11209936
J Neuropathol Exp Neurol. 2008 Nov;67(11):1072-83
pubmed: 18957894
PLoS One. 2008 Jul 09;3(7):e2640
pubmed: 18612420
Am J Psychiatry. 2000 Sep;157(9):1399-405
pubmed: 10964854
Acta Neuropathol Commun. 2013 Jul 06;1:31
pubmed: 24252572
Acta Neuropathol. 2011 Jul;122(1):61-74
pubmed: 21553300
Neurobiol Dis. 2018 Jan;109(Pt B):226-248
pubmed: 28011307
J Neuropathol Exp Neurol. 2006 Apr;65(4):348-57
pubmed: 16691116
Mov Disord. 1995 May;10(3):283-7
pubmed: 7651444